1. Home
  2. ASMB vs UIS Comparison

ASMB vs UIS Comparison

Compare ASMB & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • UIS
  • Stock Information
  • Founded
  • ASMB 2005
  • UIS 1942
  • Country
  • ASMB United States
  • UIS United States
  • Employees
  • ASMB N/A
  • UIS N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • UIS EDP Services
  • Sector
  • ASMB Health Care
  • UIS Technology
  • Exchange
  • ASMB Nasdaq
  • UIS Nasdaq
  • Market Cap
  • ASMB 225.9M
  • UIS 260.2M
  • IPO Year
  • ASMB 2010
  • UIS N/A
  • Fundamental
  • Price
  • ASMB $31.43
  • UIS $2.76
  • Analyst Decision
  • ASMB Strong Buy
  • UIS Buy
  • Analyst Count
  • ASMB 5
  • UIS 4
  • Target Price
  • ASMB $44.25
  • UIS $6.38
  • AVG Volume (30 Days)
  • ASMB 141.0K
  • UIS 580.5K
  • Earning Date
  • ASMB 11-07-2025
  • UIS 11-05-2025
  • Dividend Yield
  • ASMB N/A
  • UIS N/A
  • EPS Growth
  • ASMB N/A
  • UIS N/A
  • EPS
  • ASMB N/A
  • UIS N/A
  • Revenue
  • ASMB $33,247,000.00
  • UIS $1,957,800,000.00
  • Revenue This Year
  • ASMB $14.29
  • UIS $0.98
  • Revenue Next Year
  • ASMB N/A
  • UIS $2.56
  • P/E Ratio
  • ASMB N/A
  • UIS N/A
  • Revenue Growth
  • ASMB 54.77
  • UIS N/A
  • 52 Week Low
  • ASMB $7.75
  • UIS $3.34
  • 52 Week High
  • ASMB $32.44
  • UIS $8.93
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 63.80
  • UIS 21.28
  • Support Level
  • ASMB $30.00
  • UIS $3.42
  • Resistance Level
  • ASMB $31.80
  • UIS $3.60
  • Average True Range (ATR)
  • ASMB 1.64
  • UIS 0.14
  • MACD
  • ASMB 0.07
  • UIS -0.07
  • Stochastic Oscillator
  • ASMB 77.72
  • UIS 8.40

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. Majority of revenue is from ECS segment.

Share on Social Networks: